Phase 1 Ulcerative Colitis Trial of Brilacidin Approved by UK Regulators – IBD News Today

Posted: Published on January 11th, 2020

This post was added by Alex Diaz-Granados

The United Kingdoms Medicines and Healthcare products Regulatory Agency has approved the launch of Innovation Pharmaceuticals Phase 1 trial in healthy volunteers to investigate the safety and properties of delayed-release tablets of brilacidin for the treatment of ulcerative colitis (UC). Participant screening is expected to start in the coming weeks. Brilacidin is an artificial small molecule that belongs to a new class of compounds known as defensin-mimetics. It is structurally similar to proteins naturally produced in the body that fend off bacteria and other microbes. Besides killing pathogens, the investigational therapy also lessens inflammation and promotes wound healing, while decreasing the likelihood of drug resistance. Innovation iscollaborating with BDD Pharma, using the companys proprietary OralogiK technology, to develop delayed-release brilacidin tablets that can be taken orally for targeted delivery to the colon to treat UC, a form of inflammatory bowel disease (IBD). "Its exciting to soon start, in collaboration with our IBD formulation partner, BDD Pharma, a scientifically rigorous study of brilacidins potential as a novel oral IBD drug candidate," Arthur P. Bertolino,

Excerpt from:
Phase 1 Ulcerative Colitis Trial of Brilacidin Approved by UK Regulators - IBD News Today

Related Posts
This entry was posted in Ulcerative Colitis. Bookmark the permalink.

Comments are closed.